Mitchell A. deLong - Concepedia

Author

Mitchell A. deLong

Also Known As

Kopczynski, Casey, M. deLong, M.A. deLong, Mitchell A deLong, Mitchell A. DELONG, Mitchell A. DeLong, Mitchell A. deLong, Mitchell Anthony deLong, Mitchell deLong

Publications

917

Citations

H-Index

Concepts

All Affiliations

Procter & Gamble (United States)Aerie Pharmaceuticals (United States)University of Cincinnati Medical Center University of Alberta Duke University

About

Mitchell A. deLong is an author at Procter & Gamble (United States) specializing in pharmacology, medicine, and medicinal chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	388
2	Biochemistry	5	5	97
3	Natural Sciences	3	3	67
4	Cell Biology	1	1	20
5	Chemical Biology	1	1	19

Mitchell A. deLong

Publications

840

Citations

H-Index

Page 1

	Year	Citations
Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma Cheng‐Wen Lin, Bryan W. Sherman, Lori Moore, Journal of Ocular Pharmacology and Therapeutics	2017	181
DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective <i>in vivo</i> skin lightening potency Raymond E. Boissy, Marty O. Visscher, Mitchell A. deLong Experimental Dermatology Molecular PharmacologyMedicinal ChemistryMedicinePhotocarcinogenesisCutaneous Biology	2005	154
Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma Jill M. Sturdivant, Susan M. Royalty, Cheng‐Wen Lin, Bioorganic & Medicinal Chemistry Letters Open-angle GlaucomaOphthalmologyMedicineGlaucomaTrabecular Meshwork	2016	104
Arene-alkene cycloadditions and organic synthesis Paul A. Wender, R. J. TERNANSKY, Mitchell A. deLong, Pure and Applied Chemistry HeterocyclicAlkene MetathesisArene-alkene CycloadditionsOrganic ChemistryChemistry	1990	92
Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives Smita Chawla, Mitchell A. deLong, Marty O. Visscher, British Journal of Dermatology	2008	67
<i>N</i>-Acylglycine Amidation: Implications for the Biosynthesis of Fatty Acid Primary Amides Benjamin J. Wilcox, Kimberly J. Ritenour-Rodgers, Alexander S. Asser, Biochemistry	1999	61
Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent. Saja Hamed, Penkanok Sriwiriyanont, Mitchell A. deLong, PubMed Molecular PharmacologyMedicinal ChemistryPolyphenolicsTyrosinase ActivityMedicine	2006	52
The Synthesis and Human FP Receptor Binding Affinity of 13,14-Dihydro Prostaglandin F1.ALPHA. Sulfonamides. Potential Treatments for Osteoporosis. Yili Wang, David L. Soper, Michelle J. Dirr, Chemical and Pharmaceutical Bulletin SclerostinPharmacotherapyPharmaceutical ChemistryOsteoporosisMolecular Pharmacology	2000	32
DeoxyArbutin and its derivatives inhibit tyrosinase activity and melanin synthesis without inducing reactive oxygen species or apoptosis. Smita Chawla, Kalla Kvalnes, Mitchell A. deLong, PubMed Redox SignalingTyrosinase ActivityTyrosine HydroxylaseBiochemistryMedicine	2012	20
Amidation of Salicyluric Acid and Gentisuric Acid: A Possible Role for Peptidylglycine α-Amidating Monooxygenase in the Metabolism of Aspirin Jodi L. DeBlassio, Mitchell A. deLong, Uta Glufke, Archives of Biochemistry and Biophysics Medicinal ChemistryBiosynthesisBiochemistryNatural SciencesPeptidylglycine α-Amidating Monooxygenase	2000	19

Page 1